Shire acquires biopharmaceutical company SARcode

Pharmaceuticals group Shire has acquired California-based biopharmaceutical company SARcode to build its presence in the ophthalmology therapeutic market and add a dry eye treatment, Lifitegrast, to its portfolio.

Pharmaceuticals group Shire has acquired California-based biopharmaceutical company SARcode to build its presence in the ophthalmology therapeutic market and add a dry eye treatment, Lifitegrast, to its portfolio.

Shire will make an upfront payment of $160m, and SARcode shareholders will be eligible to receive additional undisclosed payments if certain clinical, regulatory, and/or commercial milestones are achieved.

The transaction is expected to close in the second quarter, subject to regulatory approval in the US, and other customary closing conditions.

Shire said it expects to lauch the product in 2016 providing it achieves a positive outcome of the phase 3 clinical development programme and regulatory

approvals. It is acquiring the global rights to the product.

There is currently no approved treatment indication which includes symptoms of dry eye.

Shire's Chief Executive Designate, Flemming Ornskov, said: "The acquisition of SARcode is a demonstration of Shire's focus on continuing to build our research and development pipeline with innovative, well-differentiated assets that address significant unmet patient need.

"This acquisition and our recent acquisition of Premacure have the potential to provide the basis for an attractive ophthalmology business for our company, given the significant growth opportunities in this therapeutic area as well as Shire's proven expertise in specialist markets."

The share price edged 0.05% lower to 1,977p by 15:40.

NR

Recommended

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework
Investment strategy

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework

John Stepek talks to Steve Clapham, investor, analyst and author of The Smart Money Method, about the dangers in picking individual stocks and why you…
8 Apr 2021
BP looks set to return more money to shareholders as it beats expectations
Energy stocks

BP looks set to return more money to shareholders as it beats expectations

Oil major BP is to embark on a share buyback programme after significantly reducing its debts. Saloni Sardana looks at what it means for your portfoli…
6 Apr 2021
Deliveroo has hit the market – but it’s not getting the warmest welcome
UK stockmarkets

Deliveroo has hit the market – but it’s not getting the warmest welcome

Food delivery company Deliveroo made its debut on the stockmarket this morning. But with the share price sliding by 30% straight away, it’s not made t…
31 Mar 2021
Three stocks to buy now that will come back stronger after Covid-19
Share tips

Three stocks to buy now that will come back stronger after Covid-19

Professional investor Ed Wielechowski of Odyssean Capital, chooses three compelling stocks that should thrive in a post-pandemic world.
29 Mar 2021

Most Popular

The bitcoin bubble will burst: here’s how to play it
Bitcoin

The bitcoin bubble will burst: here’s how to play it

The cryptocurrency’s price has soared far beyond its fundamentals, says Matthew Partridge. Here, he looks at how to short bitcoin.
12 Apr 2021
Four investment trusts for income investors to buy now
Investment trusts

Four investment trusts for income investors to buy now

Some high-yielding listed lending funds have come through the crisis with flying colours. David Stevenson picks four of the best.
12 Apr 2021
Central banks are rushing to build digital currencies. What are they, and what do they mean for you?
Bitcoin

Central banks are rushing to build digital currencies. What are they, and what do they mean for you?

As bitcoin continues to soar in value, many of the world’s central banks are looking to emulate it by issuing their own digital currencies. But centra…
8 Apr 2021